SBIR/STTR Research Award

BIOCIDAL DENDRIMERS FOR NOVEL ANTIMICROBIAL SURFACES

Award identifier ccc0c62aea80a36b074b028ead77e0a9b590333d660b660f08e31f9239fc0f49Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$105,180

Program and phase

SBIR · Phase I

Award year

2002

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LYNNTECH INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
PMVAL8J63516
Solicitation number
Not reported
Topic code
Not reported

Research abstract

In the US, approximately 60,000 deaths occur annually from device-related, hospital-acquired (nosocomial) infections. Effective non-antibiotic infection control technologies are needed immediately to help reduce the estimated $6.5 billion per year cost associated with the two million nosocomial infections acquired every year in the US. We propose to develop a novel antimicrobial surface modification based upon biocidal dendrimers that can be applied to variety of medical devices, will prevent biofilm formation and, therefore, reduce potentially life-threatening complications caused by device-related infections. Dendrimers have attracted attention as possible antimicrobials agents due to their compact structure, high local density of functional surface groups, their unique carrier properties, and biofriendly nature. High local concentrations of active groups are extremely beneficial in terms of potency, reduced toxicity, and increased duration of action. Our goal is to develop a novel antimicrobial surface treatment that 1) can be covalently bound to the surface of variety of plastics, including polymers commonly used in medicine; 2) can be formed on both the inner and outer surfaces of complex geometries; 3) will inhibit bacterial adhesion; 4) will be lubricious; 5) will be effective against bacteria, fungi, and spores; and 6) will not promote increased resistance to traditional antibiotics.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Research funding history

1,079 SBIR/STTR records share this UEI (1988–2025). Reported award amounts total $327,411,388. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Defense, Department of Health and Human Services, National Aeronautics and Space Administration, Department of Energy, National Science Foundation, Environmental Protection Agency

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.